NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 240 filers reported holding NEKTAR THERAPEUTICS in Q3 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,142 | +414.2% | 48,897 | +396.1% | 0.00% | – |
| Q2 2023 | $5,667 | -26.8% | 9,856 | -10.5% | 0.00% | – |
| Q1 2023 | $7,738 | -70.0% | 11,007 | -3.5% | 0.00% | – |
| Q4 2022 | $25,780 | -46.3% | 11,407 | -23.1% | 0.00% | – |
| Q3 2022 | $48,000 | +2.1% | 14,833 | +19.3% | 0.00% | – |
| Q2 2022 | $47,000 | -53.5% | 12,437 | -33.2% | 0.00% | – |
| Q1 2022 | $101,000 | -62.2% | 18,626 | -5.6% | 0.00% | – |
| Q4 2021 | $267,000 | -55.9% | 19,738 | -41.4% | 0.00% | – |
| Q3 2021 | $605,000 | -75.5% | 33,702 | -76.6% | 0.00% | -100.0% |
| Q2 2021 | $2,466,000 | +40.4% | 143,719 | +63.6% | 0.00% | 0.0% |
| Q1 2021 | $1,756,000 | -16.3% | 87,824 | -28.9% | 0.00% | 0.0% |
| Q4 2020 | $2,099,000 | +2.9% | 123,466 | +0.4% | 0.00% | 0.0% |
| Q3 2020 | $2,040,000 | +210.0% | 122,954 | +332.8% | 0.00% | – |
| Q2 2020 | $658,000 | -56.2% | 28,412 | -66.3% | 0.00% | -100.0% |
| Q1 2020 | $1,504,000 | -72.1% | 84,251 | -66.3% | 0.00% | -50.0% |
| Q4 2019 | $5,399,000 | +63.5% | 250,128 | +37.9% | 0.00% | +100.0% |
| Q3 2019 | $3,303,000 | +7.2% | 181,357 | +109.4% | 0.00% | 0.0% |
| Q2 2019 | $3,082,000 | -3.6% | 86,623 | -8.9% | 0.00% | 0.0% |
| Q1 2019 | $3,197,000 | +47.8% | 95,136 | +44.5% | 0.00% | 0.0% |
| Q4 2018 | $2,163,000 | -68.0% | 65,822 | -40.6% | 0.00% | -66.7% |
| Q3 2018 | $6,756,000 | +46.3% | 110,827 | +17.2% | 0.00% | +50.0% |
| Q2 2018 | $4,617,000 | -76.2% | 94,550 | -48.3% | 0.00% | -75.0% |
| Q1 2018 | $19,419,000 | +880.3% | 182,749 | +451.0% | 0.01% | +700.0% |
| Q4 2017 | $1,981,000 | +128.5% | 33,168 | -8.2% | 0.00% | – |
| Q3 2017 | $867,000 | -9.5% | 36,138 | -26.3% | 0.00% | – |
| Q2 2017 | $958,000 | -59.3% | 49,013 | -51.1% | 0.00% | -100.0% |
| Q1 2017 | $2,351,000 | +739.6% | 100,180 | +338.4% | 0.00% | – |
| Q4 2016 | $280,000 | +1373.7% | 22,849 | +1932.8% | 0.00% | – |
| Q3 2016 | $19,000 | -62.0% | 1,124 | -67.5% | 0.00% | – |
| Q2 2016 | $50,000 | -16.7% | 3,463 | -21.3% | 0.00% | – |
| Q1 2016 | $60,000 | -16.7% | 4,402 | +3.1% | 0.00% | – |
| Q4 2015 | $72,000 | +60.0% | 4,268 | +2.9% | 0.00% | – |
| Q3 2015 | $45,000 | -86.1% | 4,148 | -83.9% | 0.00% | – |
| Q2 2015 | $323,000 | -0.6% | 25,842 | -12.4% | 0.00% | – |
| Q1 2015 | $325,000 | +424.2% | 29,492 | +641.9% | 0.00% | – |
| Q4 2014 | $62,000 | – | 3,975 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |